Regencell Bioscience Holdings Ltd (RGC) stock
Close on Nov 13, 2026Market cap $2.45BP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $2.45B
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 183.50
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$11.70M
- EPS, diluted
- -$2.37
Trading
- Previous close
- $5.13
- Open
- $5.08
- Day's range
- $4.71 – $5.08
- Volume
- 119,338
- Average volume (20 days)
- 248,219
- Beta (5 years)
- -0.59
- 52-week range
- $4.51 – $69.00
- RSI (14 days)
- 34.5
- Volatility (1 year)
- 148.0%
- Relative volume
- 0.48×
- WACC
- 7.6%
Market cap history
Month-end market cap since 2021, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | RGC | S&P 500 | Difference | RGC per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -39.7% | -3.0% | −36.6 pts | ||
| 3 months | -5.7% | -2.8% | −2.9 pts | ||
| Year to date | -76.5% | +11.5% | −88.0 pts | ||
| 1 year | -62.0% | +13.5% | −75.5 pts | ||
| 3 years | +1159.9% | +77.7% | +1082.2 pts | +132.7% | +21.1% |
| 5 years | +646.7% | +72.6% | +574.1 pts | +49.5% | +11.5% |
Nine years at a glance
Fiscal years 2018 to 2026, USD
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Regencell Bioscience filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Regencell Bioscience
Medicinal Chemicals & Botanical Products
Regencell Bioscience Holdings Limited is an early-stage bioscience firm that researches, develops, and commercializes traditional Chinese medicine (TCM) formulas. The company focuses on formulas designed to treat neurocognitive disorders and degeneration, particularly attention deficit hyperactivity disorder (ADHD) and autism spectrum disorder (ASD). It operates primarily through its subsidiary, Regencell Bioscience Limited, in partnership with an experienced practitioner to develop standardized liquid-based formulations. The target patient population and end customers consist of individuals diagnosed with ADHD and ASD, along with their families and caregivers seeking alternative or holistic treatment options.
Company profile, executives and historyRegencell Bioscience stock: common questions
What is Regencell Bioscience's stock price?
RGC closed at $4.94 on Nov 13, 2026, down 3.61% on the day. Over the past 52 weeks it traded between $4.51 and $69.00.
What is Regencell Bioscience's market cap?
Regencell Bioscience was worth $2.45B at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is RGC's P/E ratio?
Regencell Bioscience lost money over fiscal 2026 (diluted EPS -$2.37), so it has no meaningful P/E ratio.
Does Regencell Bioscience pay a dividend?
No. Regencell Bioscience has not paid a cash dividend over the last twelve months.
How has RGC stock performed over the past year?
Including dividends, RGC returned -62.0% over the past year, against +13.5% for the S&P 500.
How many RGC shares are sold short?
0M shares were sold short at the latest FINRA report, 0.62% of the float, or 1.0 days of average trading volume.
Who are Regencell Bioscience's competitors?
Companies most similar to Regencell Bioscience by business, industry and size include DFTX, BON, RAPH, ADIA, CFOO.
See a number that looks wrong?